A robotic guidance and placement system, the IGAR system can be utilized inside of a magnetic resonance imaging (MRI) bore.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the IGAR system, a robotic guidance and placement system that is compatible with magnetic resonance imaging (MRI).
Insight Medbotics, the developer of the IGAR system, noted the robotics system is the first to gain FDA clearance for use inside of an MRI bore, and is cleared for breast biopsy indications.1
Preliminary research with IGAR biopsies resulted in lower pain scores at one week as well as reduced scarring at one week and one month in comparison to manual breast biopsies.2
“Our team has long believed in the untapped potential of accessible MRI imaging, artificial intelligence and robotics together to improve quality of life for patients,” noted Fazila Seker, the CEO of Insight Medbotics. “Many teams are researching viable paths to take robotics into the MRI suite, but IGAR is the first to secure FDA clearance. This regulatory achievement advances our long-term vision, and our commitment to delivering technology that supports the future of precision medicine.”
References
1. Insight Medbotics. Insight Medbotics announces world’s first FDA-cleared, MRI-compatible robot. Cision PR Newswire. Available at: https://www.prnewswire.com/news-releases/insight-medbotics-announces-worlds-first-fda-cleared-mri-compatible-robot-301925289.html . Published September 13, 2023. Accessed September 13, 2023.
2. Anvari M, Chapman T, Barlow K, Cookson T, Van Toen C, Fielding T. Clinical safety and efficacy of a fully automated robot for magnetic resonance imaging-guided breast biopsy. Int J Med Robot. 2023;19(2):e2472. doi: 10.1002/rcs.2472.
New Literature Review Finds ChatGPT Effective in Radiology in 84 Percent of Studies
April 29th 2024While noting a variety of pitfalls with the chatbot ranging from hallucinations to improper citations, the review authors found the use of ChatGPT in radiology demonstrated “high performance” in 37 out of 44 studies.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.